Mira Pharmaceuticals Inc banner
M

Mira Pharmaceuticals Inc
NASDAQ:MIRA

Watchlist Manager
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Watchlist
Price: 1.27 USD -4.51% Market Closed
Market Cap: $53.2m

Relative Value

There is not enough data to reliably calculate the relative value of MIRA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MIRA Relative Value
Base Case
Not Available
M
Worst Case
Base Case
Best Case

Multiples Across Competitors

MIRA Competitors Multiples
Mira Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Mira Pharmaceuticals Inc
NASDAQ:MIRA
50.2m USD 0 -1.8 -6 -6
US
Eli Lilly and Co
NYSE:LLY
963B USD 14.8 46.7 31.4 33.6
US
Johnson & Johnson
NYSE:JNJ
599.3B USD 6.4 22.4 15.5 19.1
CH
Roche Holding AG
SIX:ROG
289B CHF 4.6 30.2 12.8 14.9
CH
Novartis AG
SIX:NOVN
249.4B CHF 5.6 22.7 14 18
UK
AstraZeneca PLC
LSE:AZN
237.1B GBP 5.4 30.9 17.1 24.1
US
Merck & Co Inc
NYSE:MRK
300.9B USD 4.6 16.5 10.2 12.4
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.2 7.6 8.9
US
Pfizer Inc
NYSE:PFE
155.1B USD 2.5 20 7.7 10.2
US
Bristol-Myers Squibb Co
NYSE:BMY
125.7B USD 2.6 17.8 7.4 9.2
P/E Multiple
Earnings Growth PEG
US
M
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Average P/E: 24.1
Negative Multiple: -1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.7
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22.4
7%
3.2
CH
Roche Holding AG
SIX:ROG
30.2
29%
1
CH
Novartis AG
SIX:NOVN
22.7
15%
1.5
UK
AstraZeneca PLC
LSE:AZN
30.9
26%
1.2
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
7%
1.5
US
Pfizer Inc
NYSE:PFE
20
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.8
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Average EV/EBITDA: 46.9
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
15.5
2%
7.8
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
CH
Novartis AG
SIX:NOVN
14
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17.1
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.2
3%
3.4
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Mira Pharmaceuticals Inc
NASDAQ:MIRA
Average EV/EBIT: 101.5
Negative Multiple: -6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.6
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
19.1
7%
2.7
CH
Roche Holding AG
SIX:ROG
14.9
6%
2.5
CH
Novartis AG
SIX:NOVN
18
9%
2
UK
AstraZeneca PLC
LSE:AZN
24.1
21%
1.1
US
Merck & Co Inc
NYSE:MRK
12.4
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
3%
3
US
Pfizer Inc
NYSE:PFE
10.2
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.2
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett